This article is available to subscribers. Subscribe now. Already have an account? Sign in

Original ArticleFree PreviewArchive

Prostaglandins as Mediators of Hypercalcemia Associated with Certain Types of Cancer

List of authors.
  • Hannsjoerg W. Seyberth, M.D.,
  • Gino V. Segre, M.D.,
  • James L. Morgan, M.A.,
  • Brian J. Sweetman, Ph.D.,
  • John T. Potts, Jr., M.D.,
  • and John A. Oates, M.D.

Abstract

We investigated the role of prostaglandins in the hypercalcemia associated with neoplasia. In patients with hypercalcemia and solid tumors the excretion of the major urinary metabolite of the E prostaglandins, 7 α-hydroxy-5,11-diketotetranorprostane-1,16-dioic acid (PGE-M), was significantly greater than normal, P < 0.01 (median of 58.4 and 7.1 ng per milligram of creatinine respectively). Slightly elevated values were seen in normocalcemic patients with solid tumors (14.3 ng per milligram). The levels of the metabolite were normal in hypercalcemic patients with either hematologic neoplasia or primary hyperparathyroidism. Immunoreactive parathyroid hormone was undetectable in the plasma of all hypercalcemic patients with solid tumors. Inhibition of prostaglandin synthesis by aspirin or indomethacin reduced excretion of both the urinary metabolite and serum calcium in six hypercalcemic patients with solid tumors and elevated excretion of the metabolite. These findings support the concept that prostaglandins are mediators of the hypercalcemia caused by certain solid tumors. (N Engl J Med 293:1278–1283,1975)

Funding and Disclosures

Supported in part by grants (5M01RR–95, GM-15431, AM11794 and AM04501) from the National Institutes of Health and by the John A. Hartford Foundation, Inc. (Dr. Seyberth is supported by the Deutsche Forschungsgmeinschaft, Dr. Segre is a George Morris Piersol Teaching and Research Scholar of the American College of Physicians, and Dr. Oates is the Joe and Morris Werthan Professor of Investigative Medicine).

Presented in part at the ninth annual meeting of the European Society for Clinical Investigation. Rotterdam, Holland, April 24, 1975.

We are indebted to the Vanderbilt medical house staff for collaboration in this study, to Mrs. K.G. McManus for technical assistance and to Drs. W.D. Salmon, Jr., O. Oelz and T.J. McKenna for advice and discussions.

Author Affiliations

From the departments of Medicine and Pharmacology, Vanderbilt University, School of Medicine, Nashville, TN, and the Department of Medicine, Harvard Medical School, Massachusetts General Hospital, Boston (address reprint requests to Dr. Oates at the Vanderbilt University, School of Medicine, Nashville, TN 37232).

Print Subscriber? Activate your online access.